OTUB2

Summary

OTUB2 (OTU deubiquitinase, ubiquitin aldehyde binding 2, HGNC:20351) is a protein-coding gene on chromosome 14q32.12, encoding Ubiquitin thioesterase OTUB2 (Q96DC9). Hydrolase that can remove conjugated ubiquitin from proteins in vitro and may therefore play an important regulatory role at the level of protein turnover by preventing degradation.

This gene encodes one of several deubiquitylating enzymes. Ubiquitin modification of proteins is needed for their stability and function; to reverse the process, deubiquityling enzymes remove ubiquitin. This protein contains an OTU domain and binds Ubal (ubiquitin aldehyde); an active cysteine protease site is present in the OTU domain.

Source: NCBI Gene 78990 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 37 total
• Druggable target: yes
• MANE Select transcript: NM_023112

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20351
Approved symbol	OTUB2
Name	OTU deubiquitinase, ubiquitin aldehyde binding 2
Location	14q32.12
Locus type	gene with protein product
Status	Approved
Aliases	FLJ21916, MGC3102
Ensembl gene	ENSG00000089723
Ensembl biotype	protein_coding
OMIM	608338
Entrez	78990

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000203664, ENST00000553723, ENST00000898114

RefSeq mRNA: 1 — MANE Select: NM_023112 NM_023112

CCDS: CCDS9917

Canonical transcript exons

ENST00000203664 — 6 exons

Exon	Start	End
ENSE00000659975	94038963	94039081
ENSE00000659976	94043971	94044055
ENSE00000808725	94037380	94037475
ENSE00001174850	94044586	94044780
ENSE00001402552	94045716	94048930
ENSE00002438899	94026340	94026540

Expression profiles

Bgee: expression breadth ubiquitous, 129 present calls, max score 81.13.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 2.2317 / max 61.7986, expressed in 1181 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
141198	1.6949	1037
141199	0.2783	144
141200	0.2585	144

Top tissues by expression

133 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.13	gold quality
left testis	UBERON:0004533	78.90	gold quality
right testis	UBERON:0004534	78.85	gold quality
testis	UBERON:0000473	78.13	gold quality
skin of leg	UBERON:0001511	74.85	gold quality
lower esophagus mucosa	UBERON:0035834	74.09	gold quality
zone of skin	UBERON:0000014	73.00	gold quality
cortical plate	UBERON:0005343	72.83	gold quality
ventricular zone	UBERON:0003053	71.68	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	71.50	gold quality
esophagus mucosa	UBERON:0002469	70.59	gold quality
skin of abdomen	UBERON:0001416	70.41	gold quality
adrenal tissue	UBERON:0018303	70.24	gold quality
ganglionic eminence	UBERON:0004023	70.13	gold quality
placenta	UBERON:0001987	69.82	gold quality
islet of Langerhans	UBERON:0000006	67.04	gold quality
stromal cell of endometrium	CL:0002255	65.75	gold quality
prefrontal cortex	UBERON:0000451	65.40	gold quality
superior frontal gyrus	UBERON:0002661	65.34	gold quality
endometrium	UBERON:0001295	63.83	gold quality
frontal cortex	UBERON:0001870	62.97	gold quality
bone marrow cell	CL:0002092	62.73	gold quality
rectum	UBERON:0001052	60.83	gold quality
cerebral cortex	UBERON:0000956	59.94	gold quality
right frontal lobe	UBERON:0002810	59.24	gold quality
anterior cingulate cortex	UBERON:0009835	58.86	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	58.78	gold quality
Brodmann (1909) area 9	UBERON:0013540	58.75	gold quality
right adrenal gland	UBERON:0001233	58.65	gold quality
pancreas	UBERON:0001264	58.31	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.50

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

105 targeting OTUB2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-182-5P	99.87	74.03	2589
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-629-3P	99.85	67.99	1875

Literature-anchored findings (GeneRIF, showing 17)

• Data report the first crystal structure of an OTU superfamily protein, otubain 2, at 2.1 A resolution and propose a model for otubain-ubiquitin binding. (PMID:15258613)
• Findings suggest that OTUB1 and OTUB2 negatively regulate virus-triggered type I IFN induction and cellular antiviral response by deubiquitinating TRAF3 and -6. (PMID:19996094)
• OTUB2 is a novel promoter of viability and insulin secretion in human beta cells. OTUB2 acts through the inhibition of NF-kappaB signalling. (PMID:23515685)
• OTUB2 fine-tunes the speed of double-strand break-induced ubiquitination so that the appropriate DNA repair pathway is chosen (PMID:24560272)
• Data indicate the eubiquitinating enzyme otubain2 (OTUB2) as a regulator of GLI family zinc finger 2 (Gli2) protein degradation. (PMID:30241937)
• By elucidating a novel SUMOylation-mediated control mechanism of YAP/TAZ signaling in breast cancer metastasis, we have revealed previously unknown interplay between oncogenic KRAS and EGFR signaling and YAP/TAZ protein stability. (PMID:30472188)
• Taken together, the present study provides the first evidence that OTUB2 acts as a pivotal driver in non-small cell lung cancer tumorigenesis by stabilizing U2AF2 and activating the AKT/mTOR pathway and the Warburg effect. (PMID:30662561)
• Knockdown of otubain 2 inhibits liver cancer cell growth by suppressing NF-kappaB signaling. (PMID:32003539)
• Activation and selectivity of OTUB-1 and OTUB-2 deubiquitinylases. (PMID:32265297)
• OTUB2 promotes the progression of endometrial cancer by regulating the PKM2-mediated PI3K/AKT signaling pathway. (PMID:36316812)
• Deubiquitinase OTUB2 promotes intrahepatic cholangiocarcinoma progression by stabilizing the CTNNB1-ZEB1 axis. (PMID:36858343)
• Molecular basis for recognition and deubiquitination of 40S ribosomes by Otu2. (PMID:37169754)
• RBM15 m[6] A modification-mediated OTUB2 upregulation promotes cervical cancer progression via the AKT/mTOR signaling. (PMID:37334762)
• Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1. (PMID:38167274)
• OTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition. (PMID:38701117)
• Exploring the regulatory role of FBXL19-AS1 in triple-negative breast cancer through the miR-378a-3p/OTUB2 axis. (PMID:38702967)
• OTU deubiquitinase, ubiquitin aldehyde binding 2 (OTUB2) modulates the stemness feature, chemoresistance, and epithelial-mesenchymal transition of colon cancer via regulating GINS complex subunit 1 (GINS1) expression. (PMID:39210373)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Otub2	ENSMUSG00000021203
rattus_norvegicus	Otub2	ENSRNOG00000009117
drosophila_melanogaster	CG4968	FBGN0032214
caenorhabditis_elegans		WBGENE00007718

Paralogs (1): OTUB1 (ENSG00000167770)

Protein

Protein identifiers

Ubiquitin thioesterase OTUB2 — Q96DC9 (reviewed: Q96DC9)

Alternative names: Deubiquitinating enzyme OTUB2, OTU domain-containing ubiquitin aldehyde-binding protein 2, Otubain-2, Ubiquitin-specific-processing protease OTUB2

All UniProt accessions (1): Q96DC9

UniProt curated annotations — full annotation on UniProt →

Function. Hydrolase that can remove conjugated ubiquitin from proteins in vitro and may therefore play an important regulatory role at the level of protein turnover by preventing degradation. Mediates deubiquitination of ‘Lys-11’-,‘Lys-48’- and ‘Lys-63’-linked polyubiquitin chains, with a preference for ‘Lys-63’-linked polyubiquitin chains.

Tissue specificity. Widely expressed. Expressed at higher level in brain.

Miscellaneous. In the structure described by PubMed:15258613, the Asp-48 active site of the catalytic triad is located too far to interact directly with the active site His-224. A possible explanation is that OTUB2 is in inactive conformation in absence of ubiquitin and a conformation change may move Asp-48 in the proximity of His-224 in presence of ubiquitin substrate.

Similarity. Belongs to the peptidase C65 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96DC9-1	1	yes
Q96DC9-2	2

RefSeq proteins (1): NP_075601* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003323	OTU_dom	Domain
IPR016615	Otubain	Family
IPR019400	Peptidase_C65_otubain	Family
IPR038765	Papain-like_cys_pep_sf	Homologous_superfamily
IPR042467	Peptidase_C65_otubain_sub2	Homologous_superfamily
IPR042468	Peptidase_C65_otubain_sub1	Homologous_superfamily

Pfam: PF10275

UniProt features (30 total): helix 10, strand 8, active site 3, mutagenesis site 3, turn 2, chain 1, domain 1, site 1, splice variant 1

Structure

Experimental structures (PDB)

15 structures.

PDB	Method	Resolution (Å)
5QIV	X-RAY DIFFRACTION	1.39
5QIX	X-RAY DIFFRACTION	1.39
5QIR	X-RAY DIFFRACTION	1.43
5QIQ	X-RAY DIFFRACTION	1.44
5QIO	X-RAY DIFFRACTION	1.46
5QIT	X-RAY DIFFRACTION	1.46
5QIS	X-RAY DIFFRACTION	1.53
5QIU	X-RAY DIFFRACTION	1.56
5QIY	X-RAY DIFFRACTION	1.58
5QIP	X-RAY DIFFRACTION	1.63
5QIZ	X-RAY DIFFRACTION	1.63
5QIW	X-RAY DIFFRACTION	1.71
8CMS	X-RAY DIFFRACTION	1.77
4FJV	X-RAY DIFFRACTION	2.05
1TFF	X-RAY DIFFRACTION	2.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96DC9-F1	94.23	0.89

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (4): 48; 51 (nucleophile); 224; 226 (required to orient and stabilize the active site h-224)

Mutagenesis-validated functional residues (3):

Position	Phenotype
47	affects its ability to cleave ‘k63’-linked ubiquitin.
51	loss of function in vitro.
226	abolishes deubiquitinase activity.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-5689896	Ovarian tumor domain proteases

MSigDB gene sets: 128 (showing top): GGGACCA_MIR133A_MIR133B, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, IVANOVA_HEMATOPOIESIS_MATURE_CELL, GGGTGGRR_PAX4_03, GOBP_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_REMOVAL, GOMF_CYSTEINE_TYPE_PEPTIDASE_ACTIVITY, TGANTCA_AP1_C, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN, GOBP_PROTEIN_K48_LINKED_DEUBIQUITINATION, TATA_C, RYTTCCTG_ETS2_B, SENESE_HDAC1_TARGETS_UP, GOBP_PROTEIN_K63_LINKED_DEUBIQUITINATION, CTGYNNCTYTAA_UNKNOWN

GO Biological Process (5): proteolysis (GO:0006508), protein deubiquitination (GO:0016579), protein K11-linked deubiquitination (GO:0035871), protein K63-linked deubiquitination (GO:0070536), protein K48-linked deubiquitination (GO:0071108)

GO Molecular Function (6): cysteine-type deubiquitinase activity (GO:0004843), ubiquitin binding (GO:0043130), protein binding (GO:0005515), peptidase activity (GO:0008233), cysteine-type peptidase activity (GO:0008234), hydrolase activity (GO:0016787)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Deubiquitination	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein deubiquitination	3
protein metabolic process	1
cysteine-type deubiquitinase activity	1
protein modification by small protein removal	1
cysteine-type peptidase activity	1
deubiquitinase activity	1
ubiquitin-like protein binding	1
binding	1
hydrolase activity	1
catalytic activity, acting on a protein	1
peptidase activity	1
catalytic activity	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

718 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
OTUB2	ZUP1	Q96AP4	784
OTUB2	USP8	P40818	705
OTUB2	OTUD5	Q96G74	672
OTUB2	RNF128	Q8TEB7	653
OTUB2	YOD1	Q5VVQ6	650
OTUB2	OTUD1	Q5VV17	636
OTUB2	OTUD6A	Q7L8S5	635
OTUB2	OTUD3	Q5T2D3	633
OTUB2	L3MBTL1	Q9Y468	631
OTUB2	UCHL3	P15374	614
OTUB2	RNF168	Q8IYW5	602
OTUB2	OTUD7B	Q6GQQ9	596
OTUB2	OTUD4	Q01804	591
OTUB2	TRAF6	Q9Y4K3	583
OTUB2	OTUD6B	Q8N6M0	577
OTUB2	ZRANB1	Q9UGI0	577

IntAct

106 interactions, top by confidence:

A	B	Type	Score
ARRDC3	OTUB2	psi-mi:“MI:0915”(physical association)	0.720
OTUB2	ARRDC3	psi-mi:“MI:0915”(physical association)	0.720
OTUB2	FAM168A	psi-mi:“MI:0915”(physical association)	0.670
TRIM54	OTUB2	psi-mi:“MI:0915”(physical association)	0.670
FAM168A	OTUB2	psi-mi:“MI:0915”(physical association)	0.670
OTUB2	TRIM54	psi-mi:“MI:0915”(physical association)	0.670
OTUB2	MID1	psi-mi:“MI:0915”(physical association)	0.560
REL	OTUB2	psi-mi:“MI:0915”(physical association)	0.560
TP53BP2	OTUB2	psi-mi:“MI:0915”(physical association)	0.560
OTUB2	CPSF6	psi-mi:“MI:0915”(physical association)	0.560
SIAH1	OTUB2	psi-mi:“MI:0915”(physical association)	0.560
OTUB2	LZTS2	psi-mi:“MI:0915”(physical association)	0.560
MID2	OTUB2	psi-mi:“MI:0915”(physical association)	0.560
MID1	OTUB2	psi-mi:“MI:0915”(physical association)	0.560
OTUB2	REL	psi-mi:“MI:0915”(physical association)	0.560
CPSF6	OTUB2	psi-mi:“MI:0915”(physical association)	0.560
OTUB2	SIAH1	psi-mi:“MI:0915”(physical association)	0.560
OTUB2	MID2	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (131): OTUB2 (Two-hybrid), OTUB2 (Two-hybrid), OTUB2 (Two-hybrid), OTUB2 (Two-hybrid), OTUB2 (Two-hybrid), OTUB2 (Two-hybrid), OTUB2 (Two-hybrid), OTUB2 (Two-hybrid), OTUB2 (Two-hybrid), OTUB2 (Two-hybrid), OTUB2 (Two-hybrid), LZTS2 (Two-hybrid), KRT40 (Two-hybrid), OTUB2 (Two-hybrid), UBC (Co-crystal Structure)

ESM2 similar proteins: A0AUR5, A8XDJ2, B0WTN3, B2RYG6, B3MCZ5, B3NRC6, B4GDM5, B4HR14, B4JW83, B4KT65, B4LJT9, B4MY75, B4P6M6, B4QFD2, P38747, P52788, P97355, Q05B57, Q0IH43, Q0V9S0, Q17D30, Q17QF2, Q292F0, Q29FC9, Q3SZA5, Q4VSI4, Q567B1, Q5ZJM3, Q6A4J8, Q6IE21, Q6NTW6, Q6NX27, Q6U7I1, Q7JVI3, Q7L8S5, Q7Q068, Q7TQI3, Q7ZV00, Q803R5, Q93009

Diamond homologs: A8XDJ2, B2RYG6, Q7TQI3, Q8LG98, Q96DC9, Q96FW1, Q9CQX0, Q9VL00, Q9XVR6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

37 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	34
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

969 predictions. Top by Δscore:

Variant	Effect	Δscore
14:94037374:TTTCA:T	acceptor_loss	1.0000
14:94037376:TCA:T	acceptor_loss	1.0000
14:94037378:A:AG	acceptor_gain	1.0000
14:94037379:G:GG	acceptor_gain	1.0000
14:94037379:GA:G	acceptor_gain	1.0000
14:94037379:GAGT:G	acceptor_gain	1.0000
14:94039082:G:GG	donor_gain	1.0000
14:94043966:TGTA:T	acceptor_loss	1.0000
14:94043968:TA:T	acceptor_loss	1.0000
14:94043969:A:C	acceptor_loss	1.0000
14:94044051:ATGCT:A	donor_gain	1.0000
14:94044053:GCT:G	donor_gain	1.0000
14:94044056:G:GG	donor_gain	1.0000
14:94044776:CTCAC:C	donor_gain	1.0000
14:94044777:TCAC:T	donor_gain	1.0000
14:94044779:AC:A	donor_gain	1.0000
14:94044780:CG:C	donor_loss	1.0000
14:94044781:G:GG	donor_gain	1.0000
14:94045704:T:TA	acceptor_gain	1.0000
14:94045705:G:A	acceptor_gain	1.0000
14:94045714:A:G	acceptor_loss	1.0000
14:94045715:GGAA:G	acceptor_gain	1.0000
14:94026537:TATGG:T	donor_loss	0.9900
14:94026538:ATGGT:A	donor_loss	0.9900
14:94026539:TGG:T	donor_loss	0.9900
14:94026540:GGTC:G	donor_loss	0.9900
14:94026541:G:C	donor_loss	0.9900
14:94026542:T:A	donor_loss	0.9900
14:94037371:A:AG	acceptor_gain	0.9900
14:94037372:T:G	acceptor_gain	0.9900

AlphaMissense

1564 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:94038991:G:C	R43P	0.998
14:94039009:G:T	G49V	0.998
14:94044688:C:A	R136S	0.998
14:94038990:C:A	R43S	0.997
14:94039006:A:T	D48V	0.997
14:94044689:G:C	R136P	0.997
14:94039009:G:A	G49E	0.996
14:94039013:C:A	N50K	0.996
14:94039013:C:G	N50K	0.996
14:94039024:G:T	R54M	0.996
14:94039025:G:C	R54S	0.996
14:94039025:G:T	R54S	0.996
14:94045762:C:A	A182E	0.996
14:94045900:T:A	L228H	0.996
14:94038978:T:C	F39L	0.995
14:94038980:C:A	F39L	0.995
14:94038980:C:G	F39L	0.995
14:94044703:G:C	A141P	0.995
14:94044739:T:C	F153L	0.995
14:94044741:C:A	F153L	0.995
14:94044741:C:G	F153L	0.995
14:94044769:T:C	F163L	0.995
14:94044771:C:A	F163L	0.995
14:94044771:C:G	F163L	0.995
14:94039005:G:C	D48H	0.994
14:94039006:A:C	D48A	0.994
14:94039008:G:T	G49W	0.994
14:94039016:C:G	C51W	0.994
14:94039026:G:C	A55P	0.994
14:94045742:T:G	C175W	0.994

dbSNP variants (sampled 300 via entrez): RS1000120337 (14:94034705 C>A), RS1000232721 (14:94030160 G>A), RS1000246352 (14:94039978 G>A), RS1000295939 (14:94035348 G>A), RS1000449110 (14:94035634 A>G), RS1000815814 (14:94026656 G>C), RS1000843042 (14:94039999 G>A,T), RS1000901320 (14:94034073 T>A,C), RS1001251090 (14:94045237 T>C,G), RS1001303506 (14:94045486 A>G), RS1001427009 (14:94044814 C>G,T), RS1001555725 (14:94029570 C>A), RS1001572373 (14:94035227 CCT>C), RS1001687040 (14:94034941 T>C), RS1001737080 (14:94033052 C>T)

Disease associations

OMIM: gene MIM:608338 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST90011899_20	Aspartate aminotransferase levels	4.000000e-10

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004736	aspartate aminotransferase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4630847 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases methylation, affects methylation, increases expression	4
Valproic Acid	affects cotreatment, decreases expression, increases methylation	4
(+)-JQ1 compound	decreases expression	3
Tetrachlorodibenzodioxin	affects cotreatment, decreases expression, increases expression	3
Silicon Dioxide	increases expression	2
bisphenol F	affects cotreatment, increases expression	1
AKT activator SC79	affects phosphorylation, decreases reaction	1
bisphenol A	decreases expression	1
sodium arsenate	decreases expression, increases abundance	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	increases reaction, affects binding	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
ormosil	affects binding, increases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Temozolomide	decreases expression	1
Vorinostat	affects cotreatment, decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	decreases expression, increases abundance	1
Cisplatin	affects cotreatment, increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Estradiol	affects cotreatment, increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Lucanthone	increases expression	1
Methapyrilene	increases methylation	1
Methylcholanthrene	increases reaction, affects binding	1
Methylmercury Compounds	decreases expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4605995	Binding	Inhibition of human GST-tagged OTUB2 expressed in Escherichia coli assessed as cleavage of Ubiquitin-Rhodamine110-glycine to Ubiquitin and Rhodamine110-glycine using Ubiquitin-Rhodamine110-glycine as substrate by fluorescence based analysis	Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity. — J Med Chem

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TB68	HAP1 OTUB2 (-) 1	Cancer cell line	Male
CVCL_TB69	HAP1 OTUB2 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.